LISINOPRIL TABLET

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

LISINOPRIL (LISINOPRIL DIHYDRATE)

MAH:

COBALT PHARMACEUTICALS COMPANY

ATC_code:

C09AA03

INN:

LISINOPRIL

dosage:

20MG

pharmaceutical_form:

TABLET

composition:

LISINOPRIL (LISINOPRIL DIHYDRATE) 20MG

administration_route:

ORAL

units_in_package:

30/100/500

prescription_type:

Prescription

therapeutic_area:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

leaflet_short:

Active ingredient group (AIG) number: 0121550002; AHFS:

authorization_status:

CANCELLED PRE MARKET

authorization_date:

2017-09-01

SPC

______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 1 of 44 _
_ _
_ _
PRODUCT MONOGRAPH
PR
LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
(of Lisinopril as Lisinopril Dihydrate)
Angiotensin Converting Enzyme Inhibitor
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
Canada, L5N 2B8
CONTROL NUMBER: 172480
Date of Revision:
March 4, 2014
______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 2 of 44 _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
.......................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........................